drugset / Trial / NCT04162119
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.
Timeline
- Start
- 2019-07-07
- Primary completion
- 2021-10-10
- Completion
- 2022-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA-PD1-CART Cell | Cell therapy | — | — |